期刊文献+

多发性骨髓瘤治疗后血清游离轻链比值正常化对预后的影响 被引量:6

Effect of Free Light Chain Ratio Normalization after Treatment on Prognosis of Patients with Multiple Myeloma
下载PDF
导出
摘要 本研究旨在探讨多发性骨髓瘤治疗后血清游离轻链比值(s FLCR)正常化及其对预后的影响。回顾性分析2009年1月至2013年12月我院42例多发性骨髓瘤患者的临床资料,将多发性骨髓瘤患者治疗后获得最好疗效时s FLCR持续正常超过4周的患者归为正常化轻链比患者,反之为异常轻链比患者;分析其传统预后因素对s FLCR的影响及s FLCR对患者总生存期(OS)的意义。结果表明,多发性骨髓瘤患者的年龄、ISS分期在正常化s FLCR组及异常s FLCR组之间存在统计学差异,上述两种指标对治疗后骨髓瘤s FLCR均有负性影响(P<0.05);s FLCR达到正常化血轻链比值患者具有相对较好的总生存期(P<0.01)。结论:治疗后s FLCR正常化能够初步提示多发性骨髓瘤的预后较好。 This study was aimed to investigate the normalization of serum free light chain ratio( sPLCR)after treatment of multiple myeloma( MM)and its influence on the prognosis of MM patients.The clinical data of 42 patients with MM were analyzed retrospectively from January 2009 to November 2013 in out department.According to sPLCR consecutive normalization for more 4 weeks or not after treatmentthe patients were classified in patients with mormalized sPLCR and patients with abnormalized sPLCRthen the influence of traditional prognostic factors of MM on sPLCR and effect of sPLCR on overall survival( OS)time of MM patients were analyzed.The results showed that the influence of ageISS stage displayed statistical difference between sFLCR normalization group and abnormalization groupthe age65 years and ISS stage Ⅲ negatively impacted on sFLCR normalization( P〈0.05).The response rates of patients with normalized sFLCR were as followsCR — 60%VGPR — 38.89%PR — 28.57%17 patients( 40.48%)with sFLCR normalization showed superior OSas compared with patients with sPLCR abnormalization( P 〈0.01).It is concluded that the sFLCR normalization is the independent prognostic factor for MMsuggesting that the MM patients with sPLCR normalization after treatment have superior prognosis.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2014年第6期1640-1643,共4页 Journal of Experimental Hematology
关键词 多发性骨髓瘤 血清游离轻链比值 多发性骨髓瘤预后 multiple myeloma serum free light chain ratio multiple myeloma prognosis
  • 相关文献

参考文献9

  • 1邱录贵.应重视我国多发性骨髓瘤的规范诊治及基础研究向临床的转化[J].中华血液学杂志,2013,34(4):283-285. 被引量:6
  • 2Rajkumar SV,Harousseau JL,Durie B,et al.Consensus recommendations for the uniform reporting of clinical trials:report of the International Myeloma Workshop Consensus Panel 1.Blood,2011,117(18):4691-4695.
  • 3Kan-ichi Iwama,Dai Chihara,Kenji Tsuda,et al.Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.Eur J Haematol,2013,(90):134-141.
  • 4冒晓蓓,陈协群,翟勇平,梁蓉,高广勋,马国光,于亚平,李锋.20例初诊多发性骨髓瘤血清游离轻链测定及其临床意义[J].中国实验血液学杂志,2008,16(4):829-832. 被引量:4
  • 5张森森,吴霜,屈晓燕,许戟,刘澎,陆化,吴汉新,许家仁,李建勇,陈丽娟.血清游离轻链在多发性骨髓瘤中的临床意义研究[J].中国实验血液学杂志,2013,21(4):930-935. 被引量:14
  • 6Furtado M,Shah N,Levoguer A,et al.Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphoma.Br J Haematol,2013,160(1):63-69.
  • 7Larsen JT,Kumar SK,Dispenzieri A,et al.Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.Leukemia,2013,27(4).941-946.
  • 8Ludwig H,Bo Iejack V,Crow Iey J,et al.Survival and years of life lost in different age cohorts of patients with multiple myeloma.J Clin Oncol,2010,28(9):1599-1605.
  • 9Paiva B,Martinez-Lopez J,Vidriales MB,et al.Comparison of immunofixation,serum free light chain,and immunophenotyping for response evaluation and prognostication in multiple myeloma.J Clin Oncol,2011,29(12):1627-1633.

二级参考文献30

  • 1李华,翟锬.血清κ/λ轻链比值测定对多发性骨髓瘤的诊断价值[J].国际检验医学杂志,2006,27(2):100-101. 被引量:9
  • 2Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia, 2006 ; 20 : 1467 - 1473
  • 3Kosmas C, Stamatopolos K, Stavroyianni N, et al. Molecular analysis of immunoglobulin genes in multiple myeloma. Lcuk Lymphoma, 1999; 33 : 253 - 256
  • 4Drayson M, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma, Blood, 2001 ; 97:2900 - 2902
  • 5Kalzmann JA, Clark R.l, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem, 2002; 48:1437 -1444
  • 6Bradwell AR, Cart-Smith liD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma, Lancet, 2003 ; 361:489 -491
  • 7Mead GP, Cart-Smith HD, Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol, 2004; 126:348 - 354
  • 8Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med, 2004; 351:1860 - 1873
  • 9Dispenziefi A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smol- dering( asymptomatic ) multiple myeloma. Blood, 2008 ; 111 ( 2 ) : 785 - 789.
  • 10Harding SJ, Mead GP, Bradwell AR, et al. Serum free light chains immunoassay as an adjunct to serum protein electrophoresis and im- munofixation eleetrophoresis in the detection of multiple myeloma and other B-cell malignancies. Clin Chem Lab Med, 2009 ; 47 ( 3 ) : 302 - 304.

共引文献19

同被引文献26

引证文献6

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部